One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
The two eviQ protocols treat severe kidney impairment differently: the Ewing regimen directs an alternative where the fractionated lymphoma regimen permits a reduction or alternative. The label itself supplies qualitative renal precautions, not these numeric bands.
What to reconcile: Match the malignancy, full chemotherapy protocol, intent, renal measurement and KRT. Different protocols from the same organization are not independent validation or interchangeable prescriptions.
Open this note and its source referencesProtocol-based baseline modifications coexist with the label warning about glomerular and tubular injury, including delayed effects. A baseline reduction is not proof that treatment-emergent injury is controlled.
What to reconcile: Review renal trends and tubular/electrolyte findings throughout and after treatment; consider the complete toxicity management instructions rather than continuing from a baseline table alone.
Open this note and its source referencesFor this protocol, ifosfamide is full dose at eGFR at least 60 and at 45-59, with increased adverse-event risk in the latter band. At 30-44, reduce by 20% or select an alternative protocol. At 15-29, use an alternative protocol; the page notes possible use in other circumstances but not this regimen. Below 15 without KRT, avoid and use an alternative. KRT requires multidisciplinary oncology/nephrology/pharmacology input. Reductions apply to each starting dose, not automatically to cycle duration.
RDM43-professional-ifosfamide-ifex-0a4bd876cf-C1 · Source locator: Dose modifications: Kidney dosing recommendations, ifosfamide column and preceding notes.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=ifosfamide-ifex&s1=RDM43-professional-ifosfamide-ifex-0a4bd876cf&h1=eeb35a4a294ba6a9a3840d407c798afec5a742c1c065cc1c65bc1b6dc5735a62